Sun Pharma Advanced Research Company Q2 loss widens to Rs 63 cr
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Monday reported a net loss of Rs 63.16 crore for the quarter ended September 30 of the ongoing fiscal. The company had reported a loss of Rs 2.58 crore for July-September, 2018-19.
Total income declined to Rs 19.45 crore during the second quarter as compared with Rs 65.92 crore in the year-ago period, SPARC said in a regulatory filing.
Read Also: FIRST: Sun Pharma unveils dry-eye treatment drug CEQUA in US
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd